FORUM PRIX GALIEN GALIEN INTERNATIONAL
DAKAR – SENEGAL November, 27 & 28, 2O18 THE AGENDA AFRICA NOW
www.prix-galien-international.org
Innovation to improve the Human Condition. INNOVATION TO IMPROVE THE HUMAN PRIX GALIEN GALIEN FORUM CONDITION Our mission: INTERNATIONAL The Prix Galien is more than an award: it is a A truly global program present in movement with a mandate to foster, recognize 14 countries* The Prix Galien recognizes and reward excellence in scientific innovation Our program includes a review of outstanding achievements to improve the state of human health. Building contributions from a new generation of in improving the global on an unrivaled network of top biomedical innovators representing diverse sectors in human condition through scientists including Nobel Laureates in medicine, health across 14 countries*. Our themes: the Prix Galien manages an independent, cross better cross-cultural contacts, harmonized the development of functional and geographically diverse program regulation, internal business process The Republic of Senegal is pleased to welcome you to Dakar No- innovative drugs and other of events and sponsorships to brand “the best improvements, new information technologies vember 27 and 28, 2018 for the Prix Galien International and treatments. of the best” in new medicines and diagnostics. and effective public-private partnerships can remove barriers to the commercialization of the Galien Forum, organized for the first time in Africa. Many The Prix Galien was Our scope is global, and our commitment to good medicines and expand access to these personalities, leading experts, practitioners, and researchers from created in 1970 in honor progress in medicine is both measurable and benefits to all who need them. across the globe, including Nobel Prize winners in medicine, will concrete. Our members express this through of Galien, the father of the establishment of productive relationships to 2018 will represent a new and exciting stage in take part. medical science and build lasting bridges between the commercial the evolution of the Prix Galien as the Holding these events on Senegalese soil complements focused modern pharmacology. research enterprise and local communities pre-eminent “force populaire” behind the engaged in public policy, science, finance, global scientific enterprise. With the support of national efforts to augment our contributions to domestic Worldwide the Prix Galien academic research and the media. our sponsoring organizations, our efforts will and international public health. We believe that in addition is regarded as the extend to all who see medical innovation not to education, health-a cornerstone of prosperity and innova- In addition to recognizing advances in only as an industrial policy asset but as a tion-must remain at the heart of public policies. equivalent of the Nobel promising therapies, the Prix Galien’s annual source of social progress – where private Prize in biopharmaceutical Pro Bono Humanum Award for humanitarian enterprise and public engagement combine to Indeed, education, and the training of quality care providers and administrators are inextricably research. achievements brings a unique focus to the deliver a greater public good. linked. The development of knowledge and know-how is the basis of scientific progress, including intersection between science, business and politics. The outcome we seek is guided by the We invite all communities with a commitment in the fields of medical, pharmacological, and biotechnical sciences. synthesis principle that underpins the conduct to the conduct and promotion of life sciences For this reason, ongoing commitments are critical to raising awareness and motivating young of science itself: successful innovation where innovation to contribute to this important work. people to engage in science. Such commitments pave the way for the progress and well-being of financing, physical assets, knowledge and skills are combined from many sources to move * Belgium, Canada, China, France, Germany, Greece, humanity. new ideas quickly “from the bench to the Italy, Netherlands, Poland, Russia, Spain, Switzerland, And it is this vocation that we want to nurture and invigorate by welcoming the Prix Galien Inter- bedside,” on behalf of patients everywhere. United Kingdom and the United States. national and the Galien Forum. Moreover, we live in a world where rapid cross-border transport and globalization are transforming THE MEDAL by Albert de JAEGER local public health issues into global epidemics. The HIV/AIDS, Ebola, Zika virus, and SARS epidemics serve as stark examples. Pandemic preparedness must be supported in a comprehensive and integrated way. Working together to address threats that face us all is essential. The Prix Galien medal was designed by Albert Montgomery, Marshall and Joukov; the de Jaeger (1908 – 1992), laureate of the Weizmann Institute, as well as numerous artists, This is what the Prix Galien has done since 1970, by promoting the research and development of Premier Grand Prix de Rome architectural literary figures and prominent personalities innovative health technologies, such as drugs, vaccines, and diagnostics. As such, I would like to prize. De Jaeger designed medals for such as Sacha Guitry, Marcel Proust, Henri de warmly thank Mrs. Marion Wiesel, President of the Elie Wiesel Foundation for Humanity for her prominent figures such as Pope Pius Montherlant, Paul Harris, a number of Nobel XII (at the Villa Medicis, 1937) Prize laureates, the Empress of Iran SA Farah support of this important initiative. and Pope Jean-Paul I, Presidents Diba, Princess Grace of Monaco, and others… I invite all participants to leverage the unique moment in time that these events present in support Dwight D. Eisenhower and John F. Kennedy, distinguished De Jaeger is also the architect of numerous of our common interest in nurturing innovation for health in Africa and across the world. military leaders including outstanding monuments in France and Marshals Leclerc, Koenig, throughout the world. Macky Sall President of Senegal Past Conferences of the EWF:
Facing the 21st Tomorrow’s Century: Leaders: Threats and Venice, 1995 Promises Boston, 2000 Paris, 1988 Dublin, 2014 Over the years they Participated “ Sometimes, The Future of Hope: Petra Conferences Hiroshima, 1995 of Nobel Laureates: in the Elie Wiesel Foundation’s Conferences: Petra, Jordan 2005, we must interfere. Anatomy of Hate: 2006, 2007, 2008 Boston, 1989 Nobel Laureates Notables Haifa, 1990 When human lives are endangered, when human dignity Oslo, 1990 is in jeopardy, national borders and sensitivities become Moscou, 1991 Peter Agre (Chemistry, 2003) Mairead Corrigan Maguire (Peace, 1976) Palestinian Authority New York, 1992 Zhores I. Alferov (Physics, 2000) Rudolph A. Marcus (Chemistry, 1992) Président Mahmoud Abbas irrelevant. Wherever men or women are persecuted Philip W. Andersen (Physics, 1997) Eric Maskin (Economics, 2007) King Abdullah II and because of their race, religion, or political views, that place Kenneth J. Arrow (Economics, 1976) Daniel L. McFadden (Economics, 2000) Queen Rania of Jordan must - at that moment - become the center of the universe.” Robert J. Aumann (Economics, 2005) Craig C. Mello (Medicine, 2006) Kofi Annan Outreach from the Galien Foundation is under way Richard Axel (Medicine, 2004) Robert C. Merton (Economics, 1997) First Lady Laura Bush to West African universities dedicated to medical – Elie Wiesel from his Nobel acceptance speech. Günter Blobel (Medicine, 1999) James A. Mirrlees (Economics, 1996) Pete Cashmore and pharmacy training, as well as broader health Paul D. Boyer (Chemistry, 1997) Mario Molina (Chemistry, 1995) King Juan Carlos 1st of Spain and economic studies. The Foundation is requesting Elie Wiesel and his wife, Marion, established The Elie Wiesel Foundation Aaron Ciechanover (Chemistry, 2004) Luc Montaigner (Medicine, 2008) President Bill Clinton that each university send 10 of their most promising for Humanity soon after he was awarded the 1986 Nobel Prize for Peace. John M. Coetzee (Literature,, 2003) Robert A. Mundell (Economics, 1999) First Lady Hillary Clinton students to the inaugural Galien Africa Forum, which The Foundation’s mission, rooted in the memory of the Holocaust, is to Claude Cohen-Tannoudji (Physics, 1997) Ferid Murad (Medicine, 1998) George Clooney will take place at the Palais Des Congres in Dakar, combat indifference, intolerance and injustice through international dialogue Paul J. Crutzen (Chemistry, 1995) Sir Vidiadhar Surajprasad Naipaul John De Gioia Senegal on November 27 & 28, 2018. Robert F. Curl Jr. (Chemistry, 1996) (Literature, 2001) Renee Fleming and youth-focused programs that promote acceptance, understanding and His Holiness the Dalai Lama (Peace, 1989) Ei-ichi Negishi (Chemistry, 2010) Amanda Forysth equality. The Forum will take place over two days, with the Johann Deisenhofer (Chemistry, 1988) Erwin Neher (Medicine, 1991) Richard Gere The international conferences of The Elie Wiesel Foundation for Humanity program built around the theme: “The Ethics and Richard R. Ernst (Chemistry, 1991) Marshall W. Nirenberg (Medicine, 1986) Tom Hanks serve as a catalyst for change and action. The conferences, which focus Values of Medicine and Pharmacy”. Speakers include Sir Martin J. Evans (Medicine, 2007) Shimon Peres (Peace, 1994) President Mikhail Gorbachev on themes of Peace, Education, Health, the Environment and Terrorism, Nobel Laureates and world-renowned scientific, John B. Fenn (Chemistry, 2002) Edmund Phelps (Economics, 2006) Jeff Greenfield serve to bring together Nobel Laureates and world leaders to discuss social industry, and policy leaders from within Africa and Val Logsdon FItch (Physics, 1980) John C. Polanyi (Chemistry, 1986) Vartan Gregorian across the globe, all of whom will participate in highly problems and develop suggestions for change. The Foundation hosted its Donald A. Glaser (Physics, 1960) Stanley B. Prusiner (Medicine, 1997) President of Irlande, Michael D. Higgins interactive sessions that engage the audience. inaugural conference, Facing the 21st Century: Threats & Promises, in 1988 Sheldon Glashow (Physics, 1979) José Ramos-Horta (Peace, 1996) Marvin Kalb gathering 79 Nobel Laureates in Paris. Roy Glauber (Physics, 2005) Norman F. Ramsey (Physics, 1989) Ted Koppel Paul Greengard (Medicine, 2000) Robert C. Richardson (Physics, 1996) Nicholas Kristof The Conference paved the way for a series of conferences including: The David J. Gross (Physics, 2004) Richard J. Roberts (Medicine, 1993) Bernard Kouchner Anatomy of Hate; Tomorrow’s Leaders; The Future of Hope; and the Petra Day 1: Richard F. Heck (Chemistry, 2010) Oscar Arias Sánchez (Peace, 1997) Maurice Levy Conferences of Nobel Laureates. Features intimate, highly interactive thematic workshops James. J. Heckman (Economics, 2000) Thomas C. Schelling (Economics, 2005) President Nelson Mandela addressing ethical questions underpinning such topics as drug In the United States, the Foundation has for 25 years offered the Ethics Alan J. Heeger (Chemistry, 2000) George F. Smoot (Physics, 2006) First minister of Israël Ehud Olmert pricing, access to health care, disease prevention, and open-access Essay Contest which challenges college juniors and seniors to analyze the Dudley R. Herschbach (Chemistry, 1986) Wole Soyinka (Literature, 1986) Itzhak Perlman research. The content and format of bringing together global Avram Hershko (Chemistry, 2004) Joseph E. Stiglitz (Economics, 2001) Nathalie Portman urgent ethical issues confronting them in today’s complex world. For more leaders and students in small groups draw on the rich outcomes Roald Hoffman (Chemistry, 1981) Joseph H. Taylor (Physics, 1993) Julia Roberts than 20 years, the Foundation has operated two Beit Tzipora Centers for of the Tomorrow’s Leaders Conferences, organized by the Elie Gerardus ‘t Hooft (Physics, 1999) William David Trimble (Peace, 1998) President of France, Nicolas Sarkozy Study and Enrichment in Israel. Wiesel Foundation over the past decade. Eric Kandel (Physiology or Medicine, 2000) Harold E. Varmus (Medicine, 1989) Ismail Serageldin These Centers, in Ashkelon and Kiryat Malachi, focus on educating the Day 2: Daniel Kahneman (Economics, 2002) Martinus JG Veltman (Physics, 1999) John Silber Ethiopian-Jewish community and giving Ethiopian-Israeli students the Aaron Klug Klaus von Klitzing Sting (Chemistry, 1982) (Physics, 1985) opportunity to participate fully in Israeli society. Close to one thousand boys Will bring all Forum participants together for plenary sessions Walter Kohn (Chemistry, 1998) Elie Wiesel (Peace, 1986) Uma Thurman and girls are currently enrolled in after-school programs that serve as a that synthesize the previous day’s workshop discussions and build Sir Harold W. Kroto (Chemistry, 1996) Torsten Wiesel (Medicine, 1981) Oprah Winfrey toward a thoughtful roadmap for the future, with particular model for other schools. Finn E. Kydland (Economics, 2004) Betty Williams (Peace, 1976) Pinchas Zukerman focus on African innovation and leadership for development. Yuan T. Lee (Chemistry, 1986) Oliver E. Williamson (Economics, 2009) On July 2nd, 2016, Professor Elie Wiesel passed away. Jean-Marie Lehn (Chemistry, 1987) Kurt Wüthrich (Chemistry, 2002) Today, Mrs. Marion Wiesel and the Foundation continue his work. FIRST Galien Scientific Program Co-Chairs:
FORUM Françoise Barré-Sinoussi Ph.D., Nobel Laureate, Director of the Regulation AFRICA THE AGENDA of Retroviral Infections Division and Professor at the Institut Pasteur in Paris, France universal access to essential and OTHERS medicines Hon. Awa Marie Coll-Seck MD, Minister of State, Republic of Senegal Denis Broun - Head of Government Affairs - Cipla Raymonde G. Koffi - Previous Minister for Health - Ivory Coast Paul Lalvani - Dean and Director, Empower School of Health, India Lelio Marmora - Excecutive Director - UNITAID Mabigue Ngom - Regional Director UNFPA WCARO MANAGING INFECTIOUS DISEASES & PANDEMICS Martha Smit - Partner Fasken Françoise Barre-Sinoussi - Nobel prize for Medicine 2007 - Pasteur Institut Medicines for basic infectious and non- counterfeit medicines; and patient inability to in improving the region’s performance toward Salim S. Abdool Karim - Epidemiologist - Caprisa (Center for the aids Program of Reserarch in South Africa) communicable diseases are a staple element pay. While the role that patented medicines universal access to essential drugs; and discuss of health provision – without them, many play in limiting access is often cited as well, access issues around the increasingly important John Kengsong - Director - Centre for Disease Control and Prenvention (CDC) - South Africa conditions become harder to prevent and only a handful of medicines on the WHO field of diagnostics, where preparation of the Souleymane Mboup - CEO - IRESSEF (Institute for Health Research, Epidemiological Surveillance and Training) more expensive to treat. Access to these List are proprietary. Many such products are first WHO essentials list is underway. Finally, Nicolas Meda - Minister of Health - Burkina Faso medicines are also a sign of a well-functioning included in voluntary drug donation programs the group will highlight additional novel health system able to minimize costly acute administered by the big multinational drug partnering agreements focused on emerging Infectious and other preventable diseases remain the leading introduction of improved disease surveillance capabilities; care interventions with measures to keep companies; some companies have waived the non-communicable diseases like cancer, which causes of death in sub-Saharan Africa. Top of the list of killers the integration of pandemic preparedness planning as a patients with chronic conditions stable and right to exclusivity for their patented medicines now kills 60 per cent more Africans each year is respiratory infections, followed by HIV/AIDS and diarrheal component of development aid; and increased funding for compliant over long periods of time. In spite in the poorest countries. In September 2017, than malaria; deaths from cancer in Africa disease. A major NCD, stroke and CVD, now ranks fourth on basic public health infrastructure – the first line of defense of this evidence, the World Health Organization a WHO medicines access project launched are slated to rise by 70 per cent to 2030. the list, while TB and malaria have been pushed down to fifth against the spread of infectious pathogens. In August 2016, (WHO) estimates that one-third of Africa’s in 2012 in 15 sub-Saharan African countries The Africa Access Initiative (AAI), a and sixth, respectively. The point is communicable diseases the WHO revised its anti-pandemic operations in a single 1.2 billion people lack access to the 433 with support from the European Union joint NGO and private-sector initiative continue to dominate the health landscape in the region. The integrated Emergency Health Program with an improved drugs and vaccines in its latest 20th Essential (EU) completed its work with a report citing launched last year by Seattle-based continent is a focal point for the transmission of infectious line of sight to ground-based coordination and support. Last Medicines List, most of which are off-patent significant improvements in the region’s BioVentures for Global Health jointly micro-organisms from animals to humans, which accounts for year, the World Bank, with support from Japan and Germany, generics in widespread use for decades in the pharmaceutical supply chain, particularly for with Pfizer, Takeda Pharmaceuticals, about 75 per cent of the diseases that have emerged as public established a Pandemic Emergency Facility to unlock funds to US and Europe. Eliminating this gap would, products for HIV, malaria and TB. Also cited the International Federation of health threats in recent years, including HIV, influenza and the prioritize the response to health emergencies, in real time. On according to the WHO, save 10 million lives were faster registration of essential medicines Pharmaceutical Manufacturers and deadly Ebola and Marburg viruses. Mass migrations of people the NGO front, at the 2017 World Economic Forum in Davos, worldwide every year, with the Africa region by local regulatory authorities and progress Associations (IFPMA) and the African displaced by political and military unrest has also contributed the Bill and Melinda Gates Foundation donated $100 million benefiting the most. Explanations for the toward the commitment to universal health Organization for Research and Training to the outbreak of pandemics due to the impact this has had for the launch of the Coalition for Epidemic Preparedness failure to raise access to essential medicines coverage as a basic right of citizenship. In this on cancer (AORTIC), is one prominent – and on the capacity of local institutions to respond to the health Innovations (CEPI), a joint public-private venture which over vary, but the main factors appear to be weak panel, participants will assess the current state promising – example. AAI will pool expertise needs of these vulnerable populations. The 2014 Ebola the next five years plans to speed development of new health infrastructure; distribution bottlenecks at of medicines access in Africa, linked to the and resources of each partner with the outbreak in Liberia, Sierra Leone and Guinea – which killed vaccines to treat existing transmissible pathogens like Ebola the wholesaler and pharmacy levels, especially WHO Essential Drug List benchmark; identify initial goal of supplying important, life-saving more than 11,000 people – exposed serious gaps in Africa’s while investing in new technologies to counter future threats. at the “last mile” to the waiting patient; poor ways to eliminate barriers to cooperation chemotherapy drugs to cancer patients in five preparedness to handle diseases with the potential to spread The UK-based Wellcome Trust is also involved, along with regulation of sub-standard, falsified and among various public and private stakeholders countries. globally if not controlled. This emergency, when combined major vaccine companies like J&J and a number of leading with the slow-burning toll imposed on Africa by the spread of government aid donors. Panelists will discuss the progress ADDRESSING CHRONIC MALNUTRITION HIV, has spurred demand for a more effective regional and in executing around these and other new initiatives to Ole Dibba-Wadda - Human Capital Department Director, African Developement Bank international response. While there are positive precedents address pandemic diseases in the Africa region. Improved Marie Pierre Poirier - Regional Director UNICEF WCARO like President George W. Bush’s Emergency Plan for AIDS mobilization of local resources, especially retaining scarce Relief (PEPFAR) – which celebrates its 15th year in 2018, human capital in the fields of epidemiology, health provision Pape Abdoulaye Seck - Minister of Agriculture, Senegal raising the number of Africans receiving anti-retroviral therapy and logistics, will be analyzed along with recommendations Salimata Wade - Nutritionist - Nutrition and Diet Association in Senegal from 50,000 in 2003 to 13.3 million at present – there is to improve government partnering with the private sector, Food and nutrition are critical to human development, especially during the formative years when much of an individual’s physical and a consensus that a more systemic approach is needed. including biopharma and vaccine manufacturers. Participants cognitive potential is determined, with important consequences for health status later in life. Stunted growth in children under age five The Ebola crisis revealed that existing pandemic response will apply their unique perspectives to answer the essential caused by chronic malnutrition, together with the adverse medical consequences of rising rates of young adult obesity, has thus emerged mechanisms were tardy, uncoordinated and massively under- question: are the right incentives in place for a truly integrated as a key public health agenda item for African countries. The topic is particularly urgent in light of the fact that Africa’s population is destined resourced, particularly in the availability of trained emergency approach to pandemic surveillance, preparedness and control to double in size by 2050, to 2.5 billion people. In November 2017, the WHO Regional Office for Africa published its first Africa Nutrition responders. In the last two years, work has commenced in the Africa region, the front-line of defense in the global war Report, which called for urgent action to reduce malnutrition in the 47 countries surveyed, noting that one of every three children under age in several areas to address the problem, including the against infectious disease? five in the world with stunted growth lives in Africa. It also documents a sharp rise in obesity – the number of African children classified as overweight increased by 50 percent between 2000 and 2015. Both trends carry numerous adverse consequences for public health, ranging from increased susceptibility for childhood killer diseases like malaria and TB to higher rates of debilitating long-term chronic conditions like hypertension and diabetes, which are already proliferating throughout the region at near-epidemic rates. There are also disincentives to consumer access to healthy non-processed foods from urbanization, environmental pressures on agricultural land use, and producer subsidies that distort normal market signals. Members of the panel will discuss the link between food production and sustainable agriculture practices; the effects of population growth on the food supply; the need for better information and data on the extent of malnutrition in vulnerable groups like children under age five, women of reproductive age, and the elderly; educational campaigns to fight obesity; and the distribution effects of some multilateral food aid programs. Facilitating more cross-regional and multi-functional partnerships involving field- based organizations is another topic that could be discussed. Scientific Program Co-Chairs:
FIRST Galien Françoise Barré-Sinoussi Ph.D., Nobel Laureate, Director of the Regulation FORUM of Retroviral Infections Division and Professor at AFRICA the Institut Pasteur in Paris, France THE AGENDA Hon. Awa Marie Coll-Seck MD, Minister of State, Republic of Senegal which health insurance for the african continent? the health consequences of climate change Tedros Adhanom Ghebreyesus - WHO Director General Mame Thierno Dieng - Minister of the Environment - Senegal Jean Paul Moatti - CEO - IRD (French Research Institute for Development) Although Africa contributes little to the global build-up of Recognizing the threat, all 50 of the region’s countries have Private-sector is a $35 billion market in sub-Saharan Africa, with at least on private and community-based insurance schemes in South Africa, greenhouse gases that cause climate change, the region is ratified the 2016 Paris Agreement committing to specific half of it financed directly by patients through out-of- pocket payments Namibia, Rwanda, Ghana and Senegal. In August 2016, the World likely to suffer more than other regions on the public health emissions reduction targets around the UN 1997 Framework to providers. Governments, donor agencies and independent experts Bank’s International Development Association (IDA), the Global and development front. According to the WHO, some Convention on Climate Change. However, execution around agree that increased access to care depends on expanded financing Fund, the WHO and the Africa Development Bank pledged $24 250,000 additional deaths annually due to rising sea and the Agreement’s commitments will be difficult for African through private, pre-paid group insurance schemes to supplement billion over the next three to five years toward this objective. The ground temperatures will occur worldwide between 2030 governments without technical expertise and funding from the self-pay by the wealthy and public- sector delivery of services to hope is that this broad, region-wide initiative to boost infrastructure and 2050 – with African children under the age of five among UN, the G-7 and other aid donors. the poor. However, growth of the overall health insurance market will encourage more private and venture capital investment to create the most vulnerable. Malaria, dengue, sleeping sickness and has been stymied by regional variations in licensing and regulatory health insurance products for the local market. Panelists will explore other infectious diseases are prevalent on the sub-continent In this session, panelists will review current evidence as to the standards as well as the weak financial stability of schemes due to gaps in regulation and business practice that discourage investments and very sensitive to changes in temperature patterns. Most disease state, epidemiological, social welfare and demographic unreliable information on risk exposures, including high claims to in health insurance, particularly for a growing middle-class willing to governments lack the health infrastructure and resources to impacts of climate change in Africa and recommend initiatives renewal ratios. This in turn has made the regional insurance market spend discretionary income on health; how to address the needs cope with an accompanying surge in non-communicable to fill the education/information/advocacy, financial resource less attractive to Western investors with experience in covering large of the low income and indigent populations, in line with fiscal cardiovascular and respiratory ailments as well as increased and partnership gaps needed to build local capacity to manage populations with a diversity of health conditions. Recently, however, a realities; technical improvements in risk adjustment and the malnutrition among high-risk populations like women, children the challenge. coalition of international development organizations have committed re-insurance market; and facilitating more partnerships and migrants due to lower harvests of key crops caused by heat to invest significant resources to achieve universal basic health to share risks and promote best practices and country and drought. coverage for all Africans, including extending successful precedents learnings, for the benefit of the entire region. financing africa’s healthcare which plan for non communicable diseases? Gargee Gosh - Director of Development Policy and Finance - Bill & Melinda Gates Foundation Abdoulaye Diouf Sarr - Minister of health, Senegal Awa Marie Coll Seck - Minister of Health - Senegal Africa has a resource gap in health capital markets, marked by limited debt remain limited, as evidenced by the fact Bernard Colombo - Chairman - Roche Diagnostic characterized by the lack of physical plant – financing; and exposure to financial and that the World Bank’s International Finance Matshido Moeti - Regional Director WHO Africa infrastructure – as well as the human capital political risk, from a lack of due diligence to Corporation (IFC) is still the biggest investor Stanley Okolo - Directeur General OOAS required to make productive use of the troubles finding trustworthy local partners. in private-sector health care in Africa today. resources it has. Capacity in health lags far Another factor is the failure to stimulate the Chronic non-communicable diseases (NCDs) are a by-product of development, so it is no surprise that their incidence is behind demand for health services, creating forces of entrepreneurship that exist at the Given the continued challenges to funding growing rapidly in Africa. According the WHO Regional Office, the region will see a 27 per cent increase in the four major a vicious cycle in which the growing burden grassroots in every country. This makes it health care infrastructure, the Forum panel categories of NCDs – CVD, cancer, chronic respiratory conditions and Type II diabetes – over the next 10 years. This is of disease thwarts the productivity gains hard to foster more community engagement will work to define priorities to drive the the highest rate of expansion in NCDs in the world, and is largely a consequence of factors from outside the health sector necessary to ensure future growth in living among key stakeholders like hospitals, allocation of investment capital over the such as urbanization, trade, economic conditions, and lifestyle choices involving physical exercise, nutrition and tobacco standards and GDP – the “health is wealth” physicians, and drug manufacturers to drive next five years. A set of recommendations and alcohol use. The result is that a transition is underway in which the traditional emphasis on health interventions to effect. the development of more locally sourced to improve the incentives for mobilization attack communicable diseases linked to poverty must be accompanied by a much broader, multi-faceted set of policies products and services linked to the concept of private investment, from both domestic for NCDS. In fact, by 2030 the number of deaths in Africa attributable each year to NCDs will exceed deaths from Adding to the challenge are the pressures of “frugal,” needs appropriate innovations. and foreign sources, will be discussed, along infectious, communicable conditions. This means that priorities of governments in the region will need to change, with on public financing of health care from with best practices to spur more partnerships a greater emphasis on primary care, prevention, early diagnosis, and out-patient treatment – all of which require in turn competing domestic and national security An active private-sector role in health among key financial stakeholders – costly investments in infrastructure, people and resources that pose a significant challenge to the financing of public health priorities as well as declining foreign aid infrastructure investment is vital if Africa is to multilateral lending facilities, NGOs, systems. More attention also has to be paid to the management of disability and co-morbidities. And doing that demands disbursements. According to Deloitte’s see progress against the combined burden philanthropic foundations, governments, better information of patient health status over the long-term based on strategies that emphasize a grassroots, community- annual Africa Construction Trends 2017 of communicable and non-communicable sovereign wealth funds and others. Finally, driven approach to the overall well-being of the patient, otherwise known as population health. Panelists will reflect on report, there is very little large-scale disease, the incidence of which will grow panelists will examine progress in creating the elements of a comprehensive strategy for NCDs, taking into account the nine targets contained in the WHO’s 2020 investment in health care: only 0.3 per cent as the region’s population doubles over infrastructure in pharmaceutical regulation, Global Action Plan on NCDs. How to harness the potential of private industry, NGOs and other community-based groups in of the total value of the region’s infrastructure the next few decades. There is unanimous manufacturing and supply chain logistics in treating the “whole patient” is another theme, along with making the case for more funding for screening, diagnostics, drugs projects focused on health, far behind agreement among governments that the pharmaceutical sector and what other and medical devices that can be used in both urban and rural settings. Progress in defining, collecting and applying statistics energy/power and transport, at 21 and 16 public initiatives alone will not be enough actions should be taken to stimulate growth of NCD issues that can be shared among governments as a basis for informed policy-making will be reviewed as well. per cent, respectively. On the private-sector to deliver the health capacity patients at in what is forecast to be a market worth as front, investors in health care assets face a every level of income should be entitled much as $60 billion annually by 2020. complex regulatory environment; scalability to expect. Nevertheless, private sector problems due to siloed geographies; weak financing vehicles like venture capital (VC) Among THE PREVIOUS GALIEN An UNRIVALED REPUTATION FOR forum INTELLECTUAL RIGOR AND INTEGRITY… SPEAKERS The Prix Galien USA Committee, a group of highly accomplished individuals from the scientific and research communities, will judge which among the candidates, independent of any category, is the Best Pharmaceutical Agent (i.e. small molecule), is the Best Biotechnology Product and which is the Best Medical Technology approved by the FDA in the past ten years. As few as one or as many as three prizes may be awarded in each of these categories, and from time to time the committee may decide on awards hors prix. The prizes are awarded for products and agents that improve the human condition.
Richard Axel, MD Cori Bargmann PhD Michael Bloomberg Michael S. Brown Dr Samantha Budd Rory Collins Mikael Dolsten, MD, PhD Nobel Laureate Rockefeller University Former Mayor Nobel Laureate Vice President Co-director President, Worldwide Co-director City of New York Professor of Molecular Neuroscience iMed, University of Oxford Research and Development Kavli Institute Genetics and Internal AstraZeneca R&D Clinical Trials Unit Pfizer for Brain Science, Medicine Columbia University UT Southwestern Medical Medical Centre Center at Dallas
Ezekiel Emanuel, MD, PhD Kenneth C. Frazier Maria C. Freire, PhD Laurie Glimcher, MD Joseph Goldstein Dr Alex Gorsky Vice Provost for Global Chaiman, CEO and President & Executive CEO and President Nobel Laureate Chaiman and CEO Initiatives; Chair, President, Director Dana Farber Cancer Professor of Molecular Johnson & Johnson Dept. of Medical Ethics Merck Foundation for the National Institute; Genetics and Internal and Health Policy Levy Institutes of Health Professor of Medicine Medicine University Professor Perelman Harvard Medical School UT, Southwestern Medical School of Medicine and The Center at Dallas Wharton School, University of Pennsylvania Elie Wiesel, Peace Nobel Laureate; Paul Greengard, PhD William N. Hait, Margaret A. Hamburg, MD Eric R. Kandel, MD Sachin H. Jain, MD, MBA Nobel Laureate MD, PhD Former Commissioner Nobel Laureate Chief Medical information BAN Ki-moon, General Secretary, United Nations; Professor of Molecular Global Head, Research U.S. Food and Drug Professor of Physiology and innovation officer and Cellular Neuroscience and Development Administration and Cellular Biophysics Merck and Co.; Bill Clinton & Philippe Douste-Blazy, Rockefeller University Janssen Research Columbia University; Lecturer in Healthcare 2010 Prix Galien Pro Bono Humanum Award Laureate & Development Director Bio-technology Policy Harvard Medical Study Center, NYU School School of Medicine John Lechleiter Dr Jeffrey Leiden Donald Lloyd-Jones Joel S. Marcus Mark McClellan, MD, PhD Dr Ira Mellman Tara Narula, MD, FACC Who was Galien? Chairman and CEO Chairman, President Chairman, Department Chairman, CEO & Founder Director Vice President Medical Contributor Eli Lilly & Cie and CEO of Preventive Medicine Alexandria Real Estate Duke-Robert J. Margolis Research Genentech “CBS This Morning” Veritex Northwestern University Equities / Center for Health Policy; Born in 131AD, Galen (Galien in French) is inspired the direction of his life. When he world, studying local plants and remedies, Alexandria Venture Professor of Business, Investments; Co-Founder Medicine, and Health Policy considered the father of modern medicine was 17, Galen worked as a physician to eventually describing 473 original drugs and Alexandria Summit Duke University and pharmacology.As an anatomist, the gladiatorial school. At the age of 37, many substances of mineral and vegetable physiologist, clinician and researcher, Marcus Aurelius summoned him to Rome, origin. Importantly, Galen was the first to Guido Rasi Michael Rosenblatt, MD Bengt Samuelsson, George A. Scangos, PhD Dr Morgan Sheng Steven H. Stein, MD Executive Director Chief Medical Officer MD, PhD Chief Executive Officer Vice President Senior Vice President his work formed the basis of a school where he grew in reputation and stature codify the art of preparing active drugs European Medicines Flagship Ventures Nobel Laureate Biogen Idec Neuroscience Genentech US Clinical Development of thought known as “Galenism”, which as a healer, teacher, researcher and writer. using multiple ingredients. Galen’s faculties Agency Former President & Medical Affairs Karolinska Institute Novartis Oncology US dominated medicine until the Renaissance. His ideas on the functioning of the human of observation, logic and deduction made Former Chairman Nobel Foundation In fact, Galen’s works were used as primary body were so well received that he became him the true successor of Hippocrates, medical reference for nearly two centuries. the personal doctor of young Commodus, and his declaration that the primary aim of
Marc Tessier-Lavigne PhD P. Roy Vagelos Bert Vogelstein George Yancopoulos, Krishna Yeshwant, MD Elias Zerhouni the heir to the Emperor. He died in 201AD. medicine was patient care formed the very President M.D., Retired Chairman Professor MD, PhD General Partner President, Global R&D Raised in Pergamos, he studied in Smyrna, During his long and eminent career, Galen cornerstone of modern pharmacy.To quote Stanford University and CEO, Merck & Co., Inc. Johns Hopkins Medical Chief Scientific Officer Google Ventures Sanofi Chairman of the Board, School Regeneron Pharmaceuticals Corinth, and Alexandria, the three centers completed over five hundred learned works Jean-Pierre Changeux, “Galen first showed Regeneron Pharmaceuticals President, Regeneron Laboratories of medical excellence in the ancient world. addressing anatomy, physiology, pathology, that our mind was in the brain, not in our Legend has it that Galen was visited medical theory and practice, and many hearts.” It can be said that this was the by Aesclapius in a dream and that this forms of therapy. He traveled throughout the beginning of experimental medicine. Committee Prix Galien International* A record of leadership in bringing the best of biomedical discovery to the attention CHAIR Susan DESMOND-HELLMANN of the world… M.D., M.Ph. Chief Executive Officer of the Bill & Melinda Gates Foundation. Seattle, WA - USA
Belgium - Luxemburg - Romain LEFEBVRE The Prix Galien is the right I welcome you to the Full professor of pharmacology at Ghent University, “ event, on the right issue at the “ annual Prix Galien awards Ghent University, PhD Pharmacology right time. I thank the Galien for innovative excellence Canada - Dre Jean GRAY Foundation for bringing us in biomedical products Emeritus Professor - Continuing Medical Education - together and for recognizing and health technologies. Medicine and pharmacology - University of Dalhousie that a healthier world is a safer world and a The awards are among the highest honors more just world. in science and commerce. France - Jean-Louis Prugnaud BAN Ki-moon - 2010” Jimmy Carter - 2017 ” Member, National Academy of Pharmacy; Pharmaceutical Expert Consultant in Biotherapy; Former Chief Pharmacist, AP-HP (public hospital system of Paris); Member, former AMM Commission (market authorization); and Past President, Gene & Cell Therapy Commission The Prix Galien is a prestigious Germany - Erland ERDMANN “ award, a magnificent occasion I am particularly grateful to University of Cologne | UOC -Division of Cardiology, “ to pay recognition to our receive this award. Pneumology, Angiology and Intensive Care - Köln ” researchers and to encourage Bill Clinton - 2010 Greece - Aristeidis A. N. PATRINOS our industry. National Technical University of Athens Ph.D. Jean Chretien - 1994 ” Northwestern University. Senior Vice President for Corporate Affairs in Synthetic Genomics Inc (SGI). member of the committee for the Economic and Environmental Impacts of Increasing Biofuels Production of the U.S. National Academy of Science, of the U.S. DOE exascale computer team, of the American I know the importance of the It is a pleasure to congratulate Association for the Advancement of Science, the “ “ all those who promote the Prix American Meteorological Society Prix Galien which rewards Galien and pharmaceutical every year therapeutic research: they play a vital role Italy - Pier Luigi CANONICO innovations and research Full Professor of Pharmacology, Università del Piemonte in the fight against disease Orientale Amedeo Avogadro works among the most creative. ” throughout the world. Emmanuel Macron - 2018 John Major - 1996 ” The Netherlands - Jan DANSER Professor of Pharmacology and heads the Division of Pharmacology within the Pharmacology and Vascular Medicine Sector of the Department of Internal Medicine at the Erasmus MC. Rotterdam
Poland - Cezary SZCZYLIK Polish professor of medical science specializing in “ The Prix Galien is a welcome “ The Prix Galien since 1970 is oncology, hematology and internal diseases initiative to stimulate creative dedicated to promoting the research and promote research and development Russia - Vladimir TROFIMOVITCH excellence. of the medicine President of Russian Gastroenterological Association Barack Obama” - 2008 and medicine industries. Switzwerland - Christoph RENNER ” Prof. Dr. med. - Haematology - General Internal Macky Sall - 2018 Medicine - Medical Oncology
UK - Sir Michael RAWLINS Chair of MHRA and founding Chair of NICE
* The Prix Galien International Committee is composed of chairs from the member nations.
PCO France : Regimedia PCO Senegal : Africa Global 17 Rue de Seine Residence Waterfront 92100 Boulogne Billancourt Route de la corniche Tel : + 33 1 72 33 91 15 Dakar – Senegal